BamSEC and AlphaSense Join Forces
Learn More

Oncternal Therapeutics Inc.

Formerly NASDAQ: ONCT
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 42 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Amended and Restated License Agreement Between Oncternal Oncology, Inc. and the Regents of the University of California for Case No. Sd2005-212 Case No. Sd2010-306 Case No. Sd2011-178 Case No. Sd2012-143 Case No. Sd2012-403 Case No. Sd2015-027 Case No. Sd2015-200 Case No. Sd2018-253 Case No. Sd2019-278 Case No. Sd2021-258 Case No. Sd2024-045 Uc Agreement Control No. 2024-0966
12/34/56
EX-10.1
from 10-Q 4 pages Non-Employee Director Compensation Program
12/34/56
EX-10.5B
from 10-K 5 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Second Amendment to the Amended and Restated License Agreement Between the University of Tennessee Research Foundation and Oncternal Therapeutics, Inc
12/34/56
EX-10.17
from 10-K 17 pages Eligibility
12/34/56
EX-10.16
from 10-K 19 pages Eligibility
12/34/56
EX-10.15
from 10-K 19 pages The Purpose of the Plan Is to Advance the Interests of the Company’s Stockholders by Enhancing the Company’s Ability to Attract, Retain and Motivate Persons Who Make (Or Are Expected to Make) Important Contributions to the Company by Providing Such Persons With Equity Ownership Opportunities and Thereby Better Aligning the Interests of Such Persons With Those of the Company’s Stockholders. Capitalized Terms Used in the Plan Are Defined in Section 11 Below. 2. Eligibility. Service Providers Are Eligible to Be Granted Awards Under the Plan, Subject to the Limitations Described Herein. 3. Administration and Delegation
12/34/56
EX-10.14
from 10-K 4 pages Oncternal Therapeutics, Inc. Non-Employee Director Compensation Program This Program Has Been Updated to Reflect the Company’s One-For-Twenty Reverse Stock Split Effected by the Company on January 8, 2024
12/34/56
EX-10.1
from 8-K 3 pages Amendment No. 4 to the Amended and Restated License Agreement Between Oncternal Therapeutics, Inc. and the Regents of the University of California for Uc Case Numbers Sd2005-212, Sd2020-036, Sd2011-178, Sd2012-143, Sd2012-403, Sd2015-027, Sd2015-200, Sd2018-253 and Sd2019-278
12/34/56
EX-10.1
from 10-Q 12 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Advisory Services Agreement
12/34/56
EX-10
from 10-Q 4 pages March 31, 2023 1. 2023 Annual Bonus
12/34/56
EX-10
from 10-Q 4 pages Chase C. Leavitt Oncternal Therapeutics, Inc. Dear Mr. Leavitt: Oncternal Therapeutics, Inc. (The “Company”) Is Providing This Letter Agreement to Set Forth Agreements Between You and the Company Related to Your Compensation. This Letter Agreement Amends the Employment Agreement Between You and the Company, Dated April 12, 2021 (The “Employment Agreement”). 1. 2023 Annual Bonus
12/34/56
EX-10
from 10-Q 4 pages Richard Vincent Oncternal Therapeutics, Inc. Dear Mr. Vincent: Oncternal Therapeutics, Inc. (The “Company”) Is Providing This Letter Agreement to Set Forth Agreements Between You and the Company Related to Your Compensation. This Letter Agreement Amends the Employment Agreement Between You and the Company, Dated September 12, 2019 (The “Employment Agreement”). 1. 2023 Annual Bonus
12/34/56
EX-10
from 10-Q 4 pages March 31, 2023 1. 2023 Annual Bonus
12/34/56
EX-10
from 10-Q 4 pages March 31, 2023 1. 2023 Annual Bonus
12/34/56
EX-10
from 10-Q 4 pages March 31, 2023 1. Base Salary Reduction 2. 2023 Annual Bonus Notwithstanding Anything to the Contrary Contained in Section 3(b) of Your Employment Agreement or the Company’s Annual Incentive Plan, You Hereby Agree That You Will Not Be Eligible to Receive an Annual Bonus Relating to Performance During 2023. 3. Retention Bonus
12/34/56
EX-10
from 10-K 7 pages Oncternal Therapeutics Inc. Annual Incentive Plan
12/34/56
EX-10.1
from 10-Q 4 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. First Amendment to the Amended and Restated License Agreement Between the University of Tennessee Research Foundation and Oncternal Therapeutics, Inc
12/34/56
EX-10.19.3
from 10-K 1 page Amendment No. 2 to Oncternal Therapeutics, Inc. 2021 Employment Inducement Incentive Award Plan
12/34/56
EX-10.19.1
from 10-K 4 pages Oncternal Therapeutics, Inc. 2021 Employment Inducement Incentive Award Plan Stock Option Grant Notice
12/34/56
EX-10.18.2
from 10-K 5 pages Oncternal Therapeutics, Inc. 2019 Incentive Award Plan Restricted Stock Unit Grant Notice
12/34/56